Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')
NCT04946227
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
52
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Pembrolizumab 200mg +Paclitaxel 80mg/m2
Sponsor
Yonsei University